JUDICIALIZAÇÃO DE MEDICAMENTOS PARA TRATAMENTO DA HEPATITE C NO ESTADO DO RIO GRANDE DO SUL, BRASIL

Bonnia Acosta Vinholes; Letícia Thomasi Jahnke Botton; Alice Hirdes

doi:10.1590/SciELOPreprints.3107

##article.authors##

Bonnia Acosta Vinholes Universidade Luterana do Brasil
Letícia Thomasi Jahnke Botton Universidade Luterana do Brasil
Alice Hirdes Universidade Luterana do Brasil https://orcid.org/0000-0003-3318-0514

DOI:

https://doi.org/10.1590/SciELOPreprints.3107

Keywords:

Health judicialization, Public Policy, Pharmaceutical Services, Hepatitis C, Health Systems

Abstract

This article aims to identify which reasons lead people to seek the Judiciary in order to obtain medication for the treatment of hepatitis C. This is a quantitative cross-sectional descriptive study where 235 judgements and lower court decisions rendered by the state of Rio Grande do Sul Court of Justice between the years of 2010 and 2020 were analyzed. The results show that the main reason why people turn to the judiciary in order to obtain medication for the treatment of hepatitis C is low-income, followed by the ones who do not fit the requirements of the Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections, lack of predictability in having the medicine in the public list, zeroed stock and when the required medicine is not in ANVISA list. The results also pointed that the health judicialization is not a phenomenon connected to low-income; that the most required drugs are Ribavirina, Interferon, Sofosbuvir and Daclatasvir; that the percentage of judicial medicine concession is 93,6%. The data obtained lead to the conclusion that there is a need to reassess the Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections, the National Plan for Viral Hepatitis and the Plan for the Elimination of Hepatitis C.